Sanofi

David Squire Thorpe

Martin Smrcina

Brian S Freed

Sandor Batori

Marcel Patek

Imre Bata

Tieu-Binh Le

Aleksandra Weichsel

Brian L Pedgrift

Veronika Bartane Bodor

Zsuzsanna Tomoskozi

Stanly John

Gerard Charles Rosse

Gyorgy Ferenczy

Gabor Szeleczky

Attila Vasas

Thomas Joseph Caulfield

Jennifer Williford Clemens

Robert S Francis

Antonio Daniel Ramos

William Shelly Wire

Jianhong Zhao

Dagmar Dasha Cabel

The present invention relates to compounds of formula 1 that are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds.

Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists

The present invention relates to novel compounds of the formula Ia: in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, wherein the substituents are as described herein. The inventive compounds have CXCR5 inhibitory activity, and are particularly useful in treating or preventing various inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, Crohn's Disease, associated with the modulation of the human CXCR5 receptor.

Substituted benzoylamino-indan-2-carboxylic acids and related compounds

This invention is directed to a 3-(amido or sulphamido)-4-(4-substituted-azinyl)benzamide or benzsulphonamide compound as defined herein. The 3-(amido or sulphamido)-(4-substituted-azinyl)benzamide or benzsulphonamide compound is useful as a inhibitor of the chemokine receptor CxCR3, and for preventing or treating a CxCR3 chemokine receptor mediated disease or condition related thereto in a patient in need of such.

Inhibitors of the chemokine receptor CxCR3

Growing community of inventors

Tucson, AZ, United States of America

David Squire Thorpe